NASDAQ:AWH

Aspira Women's Health (AWH) Stock Price, News & Analysis

$3.40
-0.10 (-2.86%)
(As of 04/23/2024 ET)
Today's Range
$3.39
$3.52
50-Day Range
$2.64
$4.96
52-Week Range
$2.31
$6.75
Volume
7,829 shs
Average Volume
30,879 shs
Market Capitalization
$41.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.45

Aspira Women's Health MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
30.9% Upside
$4.45 Price Target
Short Interest
Healthy
2.14% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.24) to ($0.86) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

771st out of 909 stocks

Diagnostic Substances Industry

10th out of 11 stocks

AWH stock logo

About Aspira Women's Health Stock (NASDAQ:AWH)

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

AWH Stock Price History

AWH Stock News Headlines

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.
A Preview Of Aspira Womens Health's Earnings
See More Headlines
Receive AWH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aspira Women's Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/23/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
N/A
Current Symbol
NASDAQ:AWH
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.45
High Stock Price Target
$5.60
Low Stock Price Target
$3.30
Potential Upside/Downside
+30.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-16,690,000.00
Net Margins
-176.74%
Pretax Margin
-182.32%

Debt

Sales & Book Value

Annual Sales
$9.15 million
Book Value
($0.23) per share

Miscellaneous

Free Float
11,813,000
Market Cap
$42.20 million
Optionable
No Data
Beta
1.61
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

AWH Stock Analysis - Frequently Asked Questions

Should I buy or sell Aspira Women's Health stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aspira Women's Health in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AWH shares.
View AWH analyst ratings
or view top-rated stocks.

What is Aspira Women's Health's stock price target for 2024?

2 equities research analysts have issued twelve-month target prices for Aspira Women's Health's stock. Their AWH share price targets range from $3.30 to $5.60. On average, they predict the company's stock price to reach $4.45 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for AWH
or view top-rated stocks among Wall Street analysts.

How have AWH shares performed in 2024?

Aspira Women's Health's stock was trading at $4.08 at the beginning of 2024. Since then, AWH stock has decreased by 16.7% and is now trading at $3.40.
View the best growth stocks for 2024 here
.

When is Aspira Women's Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AWH earnings forecast
.

How were Aspira Women's Health's earnings last quarter?

Aspira Women's Health Inc. (NASDAQ:AWH) issued its quarterly earnings results on Thursday, March, 28th. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.39) by $0.09. The firm had revenue of $2.13 million for the quarter, compared to analyst estimates of $2.70 million. Aspira Women's Health had a negative trailing twelve-month return on equity of 1,099.32% and a negative net margin of 176.74%.

When did Aspira Women's Health's stock split?

Aspira Women's Health shares reverse split on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Scott A. Carmilani's approval rating as Aspira Women's Health's CEO?

33 employees have rated Aspira Women's Health Chief Executive Officer Scott A. Carmilani on Glassdoor.com. Scott A. Carmilani has an approval rating of 92% among the company's employees. This puts Scott A. Carmilani in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 97.0% of employees surveyed would recommend working at Aspira Women's Health to a friend.

What other stocks do shareholders of Aspira Women's Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aspira Women's Health investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and

How do I buy shares of Aspira Women's Health?

Shares of AWH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AWH) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners